{
    "clinical_study": {
        "@rank": "53704", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "Drug:   BioChaperone\u00ae Combo"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Active Comparator", 
                "description": "Drug:   Humalog\u00ae Mix25"
            }
        ], 
        "brief_summary": {
            "textblock": "BioChaperone Combo is a liquid formulation containing both Insulin Glargine and Insulin\n      Lispro.\n\n      The aim of this trial is to assess the efficacy and safety of BioChaperone\u00ae Combo in\n      subjects with type 1 diabetes under a dose of 0.8 U/kg.\n\n      This trial is a phase 1 single-center, randomized, double-blinded, two-treatment, two-period\n      cross-over, 30-hour euglycaemic glucose clamp trial in subjects with type 1 diabetes\n      mellitus. Each subject will be randomly allocated to one single dose of 0.8 U/kg of\n      BioChaperone\u00ae Combo and to one single dose of 0.8 U/kg of Humalog\u00ae Mix 25 on two separate\n      dosing visits."
        }, 
        "brief_title": "A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes mellitus for at least (or equal to ) 12 months,\n\n          -  Treated with multiple daily insulin injections or insulin pump treatment for at least\n             (or equal to) 12 months,\n\n          -  Body Mass Index (BMI): 18.0-28.0kg/m2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Type 2 diabetes mellitus,\n\n          -  The receipt of any investigational product within 3 month prior to first dosing,\n\n          -  Clinically significant abnormalities, as judged by the investigator,\n\n          -  Any systemic treatment with drugs known to interfere with glucose metabolism,\n\n          -  History of alcoholism or drug/chemical abuse and any tobacco product within 5 years\n             prior to screening\n\n          -  Blood or plasma donation in the past month or more than 500mL within 3 months prior\n             to screening"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981031", 
            "org_study_id": "BC3-CT005"
        }, 
        "intervention": [
            {
                "arm_group_label": "A", 
                "description": "Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)", 
                "intervention_name": "BioChaperone\u00ae Combo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B", 
                "description": "Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)", 
                "intervention_name": "Humalog\u00ae Mix25", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin LISPRO", 
                "Insulin, NPH"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 5, 2013", 
        "location": {
            "contact": {
                "email": "Ulrike.Hoevelmann@profil.com", 
                "last_name": "Ulrike H\u00f6velmann, MD", 
                "phone": "49 (0) 2131 4018 456"
            }, 
            "contact_backup": {
                "email": "Leszek.Nosek@profil.com", 
                "last_name": "Leszek Nosek, MD", 
                "phone": "+49 (0) 2131 4018 408"
            }, 
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }, 
            "investigator": {
                "last_name": "Ulrike H\u00f6velmann", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1 Study to Assess the Efficacy and Safety of BioChaperone\u00ae Combo and Humalog\u00ae Mix 25 in Subjects With Type 1 Diabetes", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "End of action of 0.8 U/kg BioChaperone\u00ae Combo (time from administration until blood glucose concentration is consistently above 8.3 mmol/L during the glucose clamp procedure)", 
            "safety_issue": "No", 
            "time_frame": "from 0 to 30 hours after a single-dose administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981031"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Compare pharmacodynamics and pharmacokinetics profiles between BioChaperone\u00ae Combo and Humalog\u00ae Mix25", 
                "safety_issue": "No", 
                "time_frame": "from 0 to 30 hours after a single-dose administration"
            }, 
            {
                "description": "hypoglycemic events, local tolerability, adverse reactions", 
                "measure": "Number of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Weeks 0-10"
            }
        ], 
        "source": "Adocia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Adocia", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}